Malcolm A Leissring

Summary

Affiliation: Mayo Clinic
Country: USA

Publications

  1. pmc Development of monoclonal antibodies and quantitative ELISAs targeting insulin-degrading enzyme
    Anthony DelleDonne
    Department of Neuroscience, Mayo Clinic, 4500 San Pablo Road S, Jacksonville, FL 32224, USA
    Mol Neurodegener 4:39. 2009
  2. pmc Designed inhibitors of insulin-degrading enzyme regulate the catabolism and activity of insulin
    Malcolm A Leissring
    Department of Neuroscience, Mayo Clinic Florida, Jacksonville, Florida, United States of America
    PLoS ONE 5:e10504. 2010
  3. pmc The AbetaCs of Abeta-cleaving proteases
    Malcolm A Leissring
    Department of Neuroscience, Mayo Clinic, Jacksonville, Florida 32224, USA
    J Biol Chem 283:29645-9. 2008
  4. pmc Insulin-degrading enzyme is exported via an unconventional protein secretion pathway
    Ji Zhao
    Department of Molecular Therapeutics, The Scripps Research Institute, Scripps Florida, 5353 Parkside Dr, Jupiter, FL 32458, USA
    Mol Neurodegener 4:4. 2009
  5. doi request reprint Optimization of peptide hydroxamate inhibitors of insulin-degrading enzyme reveals marked substrate-selectivity
    Samer O Abdul-Hay
    Department of Neuroscience, Mayo Clinic, Jacksonville, Florida 32224, USA
    J Med Chem 56:2246-55. 2013
  6. pmc Deletion of insulin-degrading enzyme elicits antipodal, age-dependent effects on glucose and insulin tolerance
    Samer O Abdul-Hay
    Department of Neuroscience, Mayo Clinic Florida, Jacksonville, Florida, United States of America
    PLoS ONE 6:e20818. 2011
  7. pmc Identification of BACE2 as an avid ß-amyloid-degrading protease
    Samer O Abdul-Hay
    Department of Neuroscience, Mayo Clinic, 4500 San Pablo Road, Birdsall Bldg, RM, 117, Jacksonville, FL 32224, USA
    Mol Neurodegener 7:46. 2012
  8. pmc Small-molecule activators of insulin-degrading enzyme discovered through high-throughput compound screening
    Christelle Cabrol
    Department of Neuroscience, Mayo Clinic, Jacksonville, Florida, United States of America
    PLoS ONE 4:e5274. 2009
  9. pmc Molecular basis for the thiol sensitivity of insulin-degrading enzyme
    Marie Neant-Fery
    Department of Molecular Therapeutics, The Scripps Research Institute, Scripps Florida, Jupiter, FL 33458, USA
    Proc Natl Acad Sci U S A 105:9582-7. 2008
  10. ncbi request reprint Proteolytic degradation of the amyloid beta-protein: the forgotten side of Alzheimer's disease
    Malcolm A Leissring
    Department of Biochemistry, The Scripps Research Institute, Scripps Florida, 5353 Parkside Dr, RE 2, Jupiter, FL 33458, USA
    Curr Alzheimer Res 3:431-5. 2006

Collaborators

Detail Information

Publications10

  1. pmc Development of monoclonal antibodies and quantitative ELISAs targeting insulin-degrading enzyme
    Anthony DelleDonne
    Department of Neuroscience, Mayo Clinic, 4500 San Pablo Road S, Jacksonville, FL 32224, USA
    Mol Neurodegener 4:39. 2009
    ..abstract:..
  2. pmc Designed inhibitors of insulin-degrading enzyme regulate the catabolism and activity of insulin
    Malcolm A Leissring
    Department of Neuroscience, Mayo Clinic Florida, Jacksonville, Florida, United States of America
    PLoS ONE 5:e10504. 2010
    ..Despite interest in pharmacological inhibition of IDE as an attractive anti-diabetic approach dating to the 1950s, potent and selective inhibitors of IDE have not yet emerged...
  3. pmc The AbetaCs of Abeta-cleaving proteases
    Malcolm A Leissring
    Department of Neuroscience, Mayo Clinic, Jacksonville, Florida 32224, USA
    J Biol Chem 283:29645-9. 2008
    ....
  4. pmc Insulin-degrading enzyme is exported via an unconventional protein secretion pathway
    Ji Zhao
    Department of Molecular Therapeutics, The Scripps Research Institute, Scripps Florida, 5353 Parkside Dr, Jupiter, FL 32458, USA
    Mol Neurodegener 4:4. 2009
    ..Further elucidation of the mechanisms underlying IDE secretion, which would be facilitated by the assays described herein, promises to uncover processes that might be defective in disease or manipulated for therapeutic benefit...
  5. doi request reprint Optimization of peptide hydroxamate inhibitors of insulin-degrading enzyme reveals marked substrate-selectivity
    Samer O Abdul-Hay
    Department of Neuroscience, Mayo Clinic, Jacksonville, Florida 32224, USA
    J Med Chem 56:2246-55. 2013
    ..Collectively, our findings demonstrate that potent, small-molecule IDE inhibitors can be developed that, in certain instances, can be highly substrate selective...
  6. pmc Deletion of insulin-degrading enzyme elicits antipodal, age-dependent effects on glucose and insulin tolerance
    Samer O Abdul-Hay
    Department of Neuroscience, Mayo Clinic Florida, Jacksonville, Florida, United States of America
    PLoS ONE 6:e20818. 2011
    ..We present here the first longitudinal characterization, to our knowledge, of glucose regulation in mice with pancellular deletion of the IDE gene (IDE-KO mice)...
  7. pmc Identification of BACE2 as an avid ß-amyloid-degrading protease
    Samer O Abdul-Hay
    Department of Neuroscience, Mayo Clinic, 4500 San Pablo Road, Birdsall Bldg, RM, 117, Jacksonville, FL 32224, USA
    Mol Neurodegener 7:46. 2012
    ....
  8. pmc Small-molecule activators of insulin-degrading enzyme discovered through high-throughput compound screening
    Christelle Cabrol
    Department of Neuroscience, Mayo Clinic, Jacksonville, Florida, United States of America
    PLoS ONE 4:e5274. 2009
    ..However, it has not been established whether the proteolytic activity of IDE can be enhanced by drug-like compounds...
  9. pmc Molecular basis for the thiol sensitivity of insulin-degrading enzyme
    Marie Neant-Fery
    Department of Molecular Therapeutics, The Scripps Research Institute, Scripps Florida, Jupiter, FL 33458, USA
    Proc Natl Acad Sci U S A 105:9582-7. 2008
    ..Moreover, this work uncovers key details about the mechanistic basis of the unusual substrate selectivity of IDE that may aid the development of pharmacological agents or IDE mutants with therapeutic value...
  10. ncbi request reprint Proteolytic degradation of the amyloid beta-protein: the forgotten side of Alzheimer's disease
    Malcolm A Leissring
    Department of Biochemistry, The Scripps Research Institute, Scripps Florida, 5353 Parkside Dr, RE 2, Jupiter, FL 33458, USA
    Curr Alzheimer Res 3:431-5. 2006
    ..This review explores the historical factors that obscured this important aspect of amyloidogenesis, and discusses the many fresh insights it offers into the causes of and potential treatments for AD...